Regal Intel Receives Grants to Study Rare Genetic Conditions
News related to:Regal Intel, Inc · 2 min read
WARREN, N.J., Nov. 12, 2026 /CourierPR/ -- Regal Intel, Inc., a 501(c)(3) nonprofit research organization, has received two seed grants to measure patient outcomes for those with rare genetic conditions. The grants, totaling $65,000 of the $145,000 awarded in NORD's latest cycle, were announced on October 1, 2026. The awards are administered by the National Organization for Rare Disorders (NORD) and selected through independent external review.
Sanjay Ahuja, Ph.D., Chief Science Officer of Regal Intel, is the principal investigator for both studies. The first, focusing on epidermodysplasia verruciformis (EV), will run for 12 months. EV is a lifelong genetic skin condition caused by variants in the TMC6 or TMC8 genes combined with persistent human papillomavirus (HPV) infection. Patients face an elevated lifetime risk of non-melanoma skin cancer, with published estimates ranging from roughly 30 to 50 percent. The study aims to produce a first measure of real-world malignancy-free survival in this population.
The second study, which will last 18 months, centers on Peutz-Jeghers syndrome (PJS). PJS is a hereditary cancer syndrome driven by germline variants in the STK11 gene. Penetrance approaches 100 percent, but the age at which patients develop serious gastrointestinal complications and malignancies varies widely between individuals. The study will correlate specific STK11 variant types with age at first emergency surgery for intussusception and with subsequent cumulative cancer risk.
Both conditions are ultra-rare, according to Orphanet. The prevalence of EV is below one per million, with more than 200 cases reported in the literature. The prevalence of PJS is estimated at one to nine per million. For the rarest conditions, a single institution may see fewer than five patients, leaving conventional statistical approaches with too little data to work with.
The studies will use NeuSymbol™, the platform developed by Regal Intel for analysis of longitudinal clinical records. Computation runs on an appliance inside the institution, and records are de-identified in place under the HIPAA Safe Harbor standard before any analysis occurs. No protected health information leaves the institutional firewall.
The EV and PJS awards were funded by those patient communities. The other two awards in the cycle went to Dr. Antonio Sommariva, Head of the Advanced Surgical Oncology Unit at the Veneto Institute of Oncology in Padova, Italy, who received $50,000 for research in appendix cancer and pseudomyxoma peritonei, funded by the ACPMP Research Foundation. Dr. Giovanna Piovani, Associate Professor of Cellular and Applied Biology at the University of Brescia, Italy, received $30,000 for research in partial trisomy 6q, funded by Dylan's Rare Chromosome Dream Team and the partial trisomy 6q community.
Regal Intel, Inc. is based in Warren, New Jersey, and works on real-world evidence methods for rare, complex, and treatment-resistant conditions. The NeuSymbol platform reads a patient record as a single picture across all encounters, identifies what is abnormal and how each value is moving, and attaches the supporting observations to every finding. Access is granted to organizations under written agreement.
The EV and PJS studies are crucial for understanding the real-world execution of surveillance guidelines and the comparative effectiveness of available treatments. The findings will provide valuable insights into how these conditions are managed and treated, potentially leading to improved patient care and outcomes.